Meeting Unmet Medical Needs
At NanoValent Pharmaceuticals, we focus our research on developing novel treatment options for patients diagnosed with glioblastoma, pancreatic cancer, ovarian cancer, and Ewing sarcoma.
Using our unique, highly optimized Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform technology, we have developed tumor-specific targeted novel format nano-ADCs like Targeted NanoSpheres (nADC/TNS), which combine drug-loaded nanoparticles with the targeting ability of monoclonal antibodies. The resulting platform technology offers several significant advantages over existing untargeted and targeted therapies.
Our unique platform technology favorably addresses key challenges in effective non-toxic drug delivery:
- Broad Utility: Our investigational nano-ADCs like Targeted Nanospheres (nADC/TNS) can effectively deliver diverse payloads, including small molecule chemotherapeutics. Our investigational lead candidate, NV103/NV105 (Irinotecan; anti-CD99), is advancing toward Investigational New Drug (IND) status, with phase 1 clinical studies expected in 2027.
- Efficacy: Dramatic tumor growth inhibition and ablation have been observed with a variety of poor prognosis, highly metastatic tumors, including Ewing sarcoma, glioblastoma, pancreatic and ovarian cancer, and adult acute lymphoblastic leukemia (ALL).
- Toxicity: No therapy-related toxicity has been observed at tumor ablative doses.
- Chemoresistance: Enhanced tumor delivery (>5X) enables higher doses with no or minimal toxicity that can overcome chemoresistance.
- Blood-Brain Barrier (BBB)/Glioblastoma (GBM): Investigational nano-ADCs like Targeted Nanospheres (nADC/TNS) readily pass through the BBB. In preclinical studies of GBM, survival was 3-fold higher than in control animals and more than 2-fold higher than with free irinotecan.